Introduction {#sec1-1}
============

Canine parvovirus (CPV) is a common etiological agent that causes severe gastroenteritis in young dogs, especially unvaccinated puppies or those with poor maternal protection through passive immunity \[[@ref1],[@ref2]\]. Parvoviruses replicate mainly in intestinal crypts and the lymphoid organs but may reach any organ in susceptible animals. The most characteristic signs of this illness are diarrhea, emesis, anorexia, depression, pyrexia, or hypothermia \[[@ref3],[@ref4]\]. CPV belongs to the genus Protoparvovirus within the family Parvoviridae, which includes the species *Carnivore protoparvovirus* 1 together with the feline panleukopenia virus (FPV), mink enteritis virus, and raccoon parvovirus \[[@ref5]\]. The viral particle shows a spherical capsid and non-enveloped structure, with a diameter of 25 nm. The genome consists of a linear and single-stranded DNA molecule that is 5.2 kb in length, with two open reading frames (ORF) \[[@ref2],[@ref6]\]. The first ORF encodes two non-structural proteins (NS1 and NS2) and the second ORF encodes two structural proteins (VP1 and VP2) that assemble the capsid with 54 units of VP1 and 6 units of VP2 \[[@ref7]\]. CPV is a variant of the FPV with the new nomenclature of canine parvovirus type 2 (CPV-2) and differs genetically and antigenically from the canine minute virus, designed as CPV-1, which causes neonatal death in dogs \[[@ref5]\]. CPV-2 became widespread since 1978, and using monoclonal antibodies, CPV-2a and CPV-2b variants were reported around the world since 1980, especially in the United States, Belgium, France, Australia, and Japan \[[@ref8],[@ref9]\].

In 2000, a third variant, designated CPV-2c, was reported in Europe using molecular methods \[[@ref10]\]. There were several mutations in the genome between the three variants and the original CVP-2, but one, in particular, has been described in codon 426 within the VP2 segment in ORF2, which consisted of the substitutions Asn (CPV-2 and CPV-2a), Asp (CPV-2b), and Glu (CPV-2c) \[[@ref9]-[@ref11]\]. All three variants (2a, 2b, and 2c) have been reported in South America since 2007, affecting young dogs from all breeds \[[@ref12]-[@ref16]\]. Immunochromatography tests, polymerase chain reaction (PCR), nucleotide sequencing, and virus isolation in Madin-Darby canine kidney cells are commonly used to detect and characterize CPVs \[[@ref17]-[@ref21]\].

The aim of this work was to detect and establish the molecular characterization of CPV affecting domestic dogs in Ecuador, based on the substitution of residue 426 in the *VP2* gene sequence, and comparing all amino acid substitutions in complete *VP2* gene with previous sequences reported in Ecuador and some selected countries around the world.

Materials and Methods {#sec1-2}
=====================

Ethical approval {#sec2-1}
----------------

Samples from animals were collected in a non-invasive manner and authorized for research use by the owners. All procedures were conducted according to the regulations of the Ethical Commission for Animal Use of the School of Veterinary Medicine, University of São Paulo.

Samples {#sec2-2}
-------

The samples were collected from different clinics located in Quito city during the months of May, June, and July in 2017 by veterinarians specialized in medicine for dogs and cats. A total of 35 fecal samples and four commercial vaccines for positive controls (C1-C4) (Canigen MHA~2~Puppy, HIPRADOG 7, Nobivac PUPPY DP, and Vanguard^®^ Plus CPV/CV) were fixed in FTA cards (GE Healthcare Company, Little Chalfont, Buckinghamshire, UK), accompanied by a basic record for each animal, filled in with information regarding age, breed, geographical zone, gender, and vaccination status. All animals reported clinical signs associated with parvovirus infections such as gastroenteritis, anorexia, and vomiting. Parvovirus was confirmed by detection with the SNAP^®^ Parvo Test (Idexx Laboratories, Westbrook, Maine, USA) before the fixation of feces in the FTA cards. All the material was stored in individual plastic bags and sent for molecular analysis to the Department of Pathology, School of Veterinary Medicine at the University of São Paulo, Brazil. All data from each sample are available in [Table-1](#T1){ref-type="table"}.

###### 

Data obtained from each positive sample for CPV.

  Clinical case number   Age (weeks)   Breed                Sex      Vaccinated   Variant CPV   Accession number
  ---------------------- ------------- -------------------- -------- ------------ ------------- ------------------
  1                      8             French poodle        Female   Yes          2a            MG264075
  2                      10            Mixed                Male     No           2a            MG264044
  3                      12            Mixed                Male     No           2c            MG264045
  4                      20            Mixed                Male     Yes          2a            MG264076
  5                      8             Miniature Pinscher   Female   No           2c            MG264046
  6                      28            Mixed                Female   No           2c            MG264047
  7                      8             Siberian Husky       Female   No           2b            MG264048
  8                      24            American bulldog     Male     Yes          2c            MG264077
  9                      16            Mixed                Female   No           2a            MG264049
  10                     8             Chihuahua            Male     Yes          2a            MG264050
  11                     8             Beagle               Male     No           2a            MG264051
  12                     10            Golden retriever     Male     NR           2a            MG264052
  13                     12            Mixed                Male     No           2c            MG264053
  14                     14            Mixed                Female   NR           2a            MG264054
  15                     28            Beagle               Female   NR           2a            MG264055
  16                     12            Mixed                Female   No           2a            MG264056
  17                     16            French poodle        Female   No           2b            MG264057
  18                     12            Mixed                Female   No           2a            MG264058
  19                     8             Siberian Husky       Female   Yes          2a            MG264059
  20                     12            Schnauzer            Male     No           2a            MG264060
  21                     12            Miniature Pinscher   Female   No           2c            MG264061
  22                     NR            NR                   Male     No           2c            MG264062
  23                     24            Mixed                Male     No           2c            MG264063
  24                     20            Mixed                Male     No           2b            MG264078
  25                     12            Mixed                Female   NR           2a            MG264064
  26                     8             German shepherd      Male     NR           2a            MG264065
  27                     NR            Mixed                Male     No           2c            MG264066
  28                     24            American pit bull    Female   No           2c            MG264067
  29                     8             Mixed                Male     No           2a            MG264068
  30                     16            Mixed                Female   No           2a            MG264069
  31                     36            Mixed                Male     No           2a            MG264070
  32                     8             Mixed                Female   No           2c            MG264071
  33                     16            Mixed                Male     No           2a            MG264072
  34                     8             Mixed                Female   No           2a            MG264073
  35                     28            Akita                Female   Yes          2c            MG264074

CPV: Canine parvovirus, NR: Not reported

DNA extraction {#sec2-3}
--------------

The circle inside the FTA card was cut with sterile scissors and suspended in 500 µl of phosphate-buffered solution, 0.1 M, pH 7.4. The material was macerated using the TissueLyser LT Bead Mill (Qiagen, Hilden, Germany) instrument for 5 min. The suspension was centrifuged for 30 min at 12,000× *g*, and 200 µl of supernatant was collected for DNA extraction using the phenol/chloroform method \[[@ref22]\]. Extracted DNA was stored at −20°C for further analysis.

PCR and DNA sequencing {#sec2-4}
----------------------

Two sets of primers were designed with the Primer3Plus free software \[[@ref23]\] based on the viral genome that encodes the *VP2* protein. The first pair of primers was designed to amplify a region of *VP2* gene that involves residue 426, which determines the classification of the three variants of the CPV-2 (VP2-F 5'-AGCAGATGGTGATCCAAGAT-3', and VP2-R 5'-TGGATTCCAAGTATGAGAGG-3') and was used for amplification of all 35 samples and 4 positive controls. The PCR reactions were carried out with a mix that contained 2.5 µl of extracted DNA, 1× PCR Buffer - Mg, 1.25 mM of each deoxynucleotide triphosphate, 0.5 µM of each primer (VP2-F and VP2-R), 1 U of Platinum Taq DNA Polymerase (Invitrogen, Carlsbad, CA, USA), 1.5 mM of MgCl~2~, and enough ultrapure DNase-free distilled water to reach 25 µl of the mixture. The following temperature conditions were used for the PCR reactions: A cycle of 94°C for 4 min, 30 cycles at 94°C for 30 s, 56°C for 45 s, and 72°C for 1 min, followed by a final extension at 72°C for 10 min. The second pair of primers was designed to cover the complete *VP2* gene (cVP2-F 5'-GGTGCAGGACAAGTAAAAAGAG-3' and cVP2-R 5'-ACCCACACCATAACAACATACA-3') and was used in samples 1, 4, 8, and 24 and the Nobivac vaccine (C3). Sample 1 was chosen randomly from all samples with the mutation Ser514Ala ([Figure-1](#F1){ref-type="fig"}), sample 4 was chosen randomly from CPV-2a samples affecting vaccinated dogs and without the mutation Ser514Ala ([Figure-1](#F1){ref-type="fig"}), sample 8 was chosen randomly from CPV-2c samples affecting vaccinated dogs ([Table-1](#T1){ref-type="table"}), and sample 24 was chosen randomly from CPV-2b samples ([Table-1](#T1){ref-type="table"}). The following temperature conditions were used for the PCR reactions: A cycle of 95°C for 4 min, 35 cycles at 95°C for 45 s, 56°C for 2 min, and 72°C for 1 min, followed by a final extension at 72°C for 10 min. PCR products were analyzed by electrophoresis on 1% agarose gels with a 100 bp DNA ladder to estimate the fragment sizes of 529 bp for the first PCR product and 2191 bp for the second PCR product. The PCR products were purified using the GPX™ PCR DNA and Gel Band Purification kit (GE Healthcare, Piscataway, New Jersey, USA) following the manufacturer's instructions. The purified products were submitted to the sequencing reaction in both directions, forward and reverse, using the BigDye^®^ Terminator Cycle Sequencing Kit v3.1 (Applied Biosystems by Life Technologies, Carlsbad, California, USA). Sequencing reactions were analyzed with an ABI 3730 DNA Analyzer (Applied Biosystems by Life Technologies).

![Alignment performed with the Clustal W method, using protein sequences of 35 samples, four positive controls, and the reference sequence of canine parvovirus variants type 2 from GenBank.](VetWorld-11-480-g001){#F1}

Phylogenetic and sequence analysis {#sec2-5}
----------------------------------

Electropherograms obtained from the sequence readings were assembled and translated into protein sequences with CLC Main Work Bench 7.7.1 software. Nucleotide and amino acid (AA) sequences were aligned using the CLUSTAL W method available in Clustal X 2.0 software. *VP2* proteins of each VP2 AA complete sequences were structured in the SWISS-MODEL system \[[@ref24]\], and residues were depicted using PyMOL software v.2.0.3. Phylogenetic analysis was inferred using the maximum likelihood statistical method integrated into MEGA 7.0.18 \[[@ref25]\] with 1000 bootstrap replications \[[@ref26]\]. Accession codes for sequences of positive controls are as follows: MG264041 (Canigen), MG264042 (Hipradog), MG264079 (Nobivac), and MG264043 (Pfizer). Complete VP2 sequences (1755 bp) were used to infer the phylogenetic tree and reference sequences were taken from the GenBank database which belonged to strains isolated from different countries around the world ([Figure-2](#F2){ref-type="fig"}).

![The evolutionary tree was inferred using the maximum-likelihood method. The percentage of trees in which the associated taxa clustered together is shown next to the branches. Initial tree for the heuristic search was obtained automatically by applying Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances estimated using the maximum composite likelihood approach and then selecting the topology with superior log-likelihood value. A discrete gamma distribution was used to model evolutionary rate differences among sites.](VetWorld-11-480-g002){#F2}

Results {#sec1-3}
=======

Data analysis {#sec2-6}
-------------

Dog breeds used in this study were not specifically selected and depended on the availability of each veterinarian clinic that helped us. A number of 19/35 (54.3%) mixed dogs and 16/35 (45.7%) dogs corresponding to different breeds without a specific pattern were obtained. Regarding age, 10/35 (28.5%) were 8 weeks' old, 2/35 (5.7%) were 10 weeks' old, 7/35 (20%) were 12 weeks' old, 5/35 (14.3%) were between 14 and 16 weeks' old, and the remaining 9/35 (25.7%) were between 20 and 36 weeks' old, with 2/35 final samples without information about the age of the dogs. Of the total, 17/35 (48.5%) animals were males and 18/35 (51.5%) were females. According to the information provided by the owner of each animal, 6/35 (17.1%) of them received an immunization with a commercial vaccine against parvoviruses, with the number of doses or any other report about the vaccination program of their pets not provided.

PCR and DNA sequencing {#sec2-7}
----------------------

All samples showed amplification of the target fragments in the first and second round PCRs (529 bp and 2191 bp, respectively) which were confirmed by agarose gel electrophoresis. The nucleotide sequences of the 35 samples and the 4 positive controls, obtained in the first round of PCRs, were translated into protein sequences, and they were aligned with a reference sequence (NP_955539) of CPV-2a obtained from GenBank. The size of the protein sequences obtained for each sample after the assembly and translation of the nucleotide sequences was approximately 168 aa, starting at residue 376 until residue 543 of the *VP2* gene. Based on the mutation located at residue 426 of CPV-2b (Asn426Asp) and CPV-2c (Asn426Glu), we found that 20/35 (57.1%) samples corresponded to CPV-2a, 12/35 (34.3%) to CPV-2c, and the remaining 3/35 (8.5%) to the CPV-2b variants. According to the aa alignment ([Figure-1](#F1){ref-type="fig"}), 15/20 (75%) samples corresponding to the CPV-2a variant showed a mutation in residue 514 (Ala-Ser), which differed from the remaining 24 sequences, including CPV-2b, CPV-2c, and the positive controls (CPV-2). To search for additional mutations in the VP2 genome from the three variants found in this study, an analysis of the complete sequence of the *VP2* gene was performed, comparing four samples selected as described in the materials and methods against the VP2 sequence of the virus present in the Nobivac (C3) vaccine corresponding to the original CPV-2. In addition, to describe the mutation in residue 426, several mutations were found in the *VP2* protein of samples 1, 4, 8, and 24 when compared with C3 (Nobivac): Met87Leu, Ile101Thr, Val219Ile, Ala300Gly, Asp305Tyr, Asn375Asp, and Lys386Gln. Sample 1 also showed additional mutations corresponding to Ser297Asn, Tyr324Ile, and Ala514Ser; samples 4, 8, and 24 had a mutation in residue Ser297Ala; samples 4 and 24 showed a mutation in Thr440Ser; sample 28 showed a mutation in residue Thr322Ser; and sample 8 showed a mutation in residue Val139Ile. All mutations in the *VP2* gene in the four samples are described in [Table-2](#T2){ref-type="table"}. The residues with mutations were localized in a three-dimensional (3D) figure of the *VP2* protein generated by the SWISS-MODEL system and depicted with PyMOL software ([Figure-3](#F3){ref-type="fig"}). The substitution of residue 514 from alanine in C3 to serine in sample 1 is illustrated in a zoomed-in view of the ribbon diagram ([Figure-4](#F4){ref-type="fig"}).

###### 

Residue mutations present in protein sequences of samples 1, 4, 8, and 24, compared with the C3 (Nobivac vaccine).

  Canine samples   Residues                                                                           
  ---------------- ---------- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- -----
  CPV-2 (C3)       Met        Ile   Val   Val   Ser   Ala   Asp   Thr   Tyr   Asn   Lys   Asn   Thr   Ala
  CPV-2a (1)       Leu        Thr   Val   Ile   Asn   Gly   Tyr   Thr   Ile   Asp   Gln   Asn   Thr   Ser
  CPV-2a (4)       Leu        Thr   Val   Ile   Ala   Gly   Tyr   Thr   Tyr   Asp   Gln   Asn   Ser   Ala
  CPV-2b (24)      Leu        Thr   Val   Ile   Ala   Gly   Tyr   Ser   Tyr   Asp   Gln   Asp   Ser   Ala
  CPV-2c (8)       Leu        Thr   Ile   Ile   Ala   Gly   Tyr   Thr   Tyr   Asp   Gln   Glu   Thr   Ala

Ala=Alanine, Asn=Asparagine, Asp=Aspartic acid, Gln=Glutamine, Gly=Glycine, Ile=Isoleucine, Leu=Leucine, Lys=Lysine, Ser=Serine, Thr=Threonine, Tyr=Tyrosine, Val=Valine, CPV: Canine parvovirus

![Ribbon diagrams of VP2 from C3 (canine parvovirus variants type 2), with the front (a) and rear (b) views, in which the 14 residues with mutations between our variants are displayed (red sections).](VetWorld-11-480-g003){#F3}

![Comparison of residue 514 from VP2 in a zoomed-in view of the ribbon diagram, between the C3 (a) and sample 1 (b), showing the substitution from alanine (Ala) in C3 (canine parvovirus variants type 2 \[CPV-2\]) to serine (Ser) in sample 1 (CPV-2a).](VetWorld-11-480-g004){#F4}

Phylogenetic analysis {#sec2-8}
---------------------

The phylogenetic tree shows an evolutionary separation between the CPV-2a, CPV-2b, and CPV-2c from Ecuadorian strains and the original CPV-2 used for vaccine production (C3). In this analysis, CPV-2a and CPV-2b were related to previous strains identified in Ecuador; however, the two strains of CPV-2a were clustered in different groups. Sample 4 clustered with a widely distributed variant of CPV-2a from around the world and sample 1 showed a more specific distribution in countries such as Argentina, Brazil, Africa, and India. Sample 8 seems to be related with a common ancestor for CPV-2b and CPV-2c strains widely distributed in Europe, Asia, and America ([Figure-2](#F2){ref-type="fig"}). Test for recombination was performed with the Recombination Detection Program software v. 4.94, using the RDP, GENECONV, MaxChi, Bootscan, and SiScan programs, showing no evidence of recombination in the results.

Discussion {#sec1-4}
==========

CPV is a widely distributed virus that affects susceptible young dogs around the world. Molecular characterization is based on typing residue 426 inside the *VP2* gene without sequencing the complete (ORF) \[[@ref27]-[@ref29]\]. In our study, we characterized 35 samples of positive CPV collected from domestic puppies with clinical signs for CPV, and we analyzed the complete *VP2* gene of 4/35 samples randomly selected for each CPV variant (CPV-2a, CPV-2b, and CPV-2c). The isolated CPV strains belong to Quito, Ecuador, where the dog population has reached an estimated 300,000 animals, of which 40% are street dogs \[[@ref30]\]. Therefore, the prevalence of CPV cannot be determined exactly. CPV-2a and CPV-2c showed the highest prevalence in our results (57.1% and 34.3%, respectively), demonstrating the spread of these variants in South America; in addition, previous studies revealed the presence of the same variants in Brazil, Argentina, Uruguay, and Ecuador, along with preliminary reports of CPV-2c in Colombia that were not yet confirmed \[[@ref13]-[@ref16],[@ref31]\]. According to the phylogenetic tree, two lineages of CPV-2a are present in Ecuador. One of them is grouped with lineages from North America, Europe, and Asia, and the second one, in addition to sharing a common ancestor with strains from Argentina, Brazil, India, and South Africa, seems to be exclusive to Ecuador, determining the possibility of viral circulation in a small geographical area of South America. Parvovirus infections are determined by an immature immunological system or a susceptible immune system in adult dogs \[[@ref2]\]. Natural infections of CPV-2c produce similar signs of CPV-2a and CPV-2b, such as vomiting, diarrhea, fever, anorexia, depression, and leukopenia, despite some studies showing reduced mortality and a less-severe clinical course in non-vaccinated puppies of 9-10 weeks of age \[[@ref11]\]. The new variants that emerged since 1970 with the almost complete worldwide replacement of CPV-2 with CPV-2a in 1980 \[[@ref32]\] and the subsequent variants CPV-2b and CPV 2c that were rapidly spread between dog populations \[[@ref7],[@ref8],[@ref33]\] became of special interest due to the new phenotypical characteristics, and the capability to adapt to host ranges different from wild and domestic dogs. Reports of severe clinical signs were obtained related to CPV-2c in domestic cats \[[@ref34]\] and the capacity of the CPV-2a and CPV-2b variants to replicate in cats \[[@ref35],[@ref36]\] including the possibility of coinfections between FPV and CPV-2a in young kittens \[[@ref37]\]. Vaccines containing the original strain of CPV-2 seem to give protection against the variant CPV-2b, showing that it prevents an increase in acute phase proteins (α-1 acid glycoprotein and serum amyloid A), lymphopenia, neutropenia, and a reduction of the levels of neutrophil-CD4 expression when experimental dogs were inoculated orally and intranasally with a strain of CPV-2b after the application of three doses of a conventional modified live CPV-2 vaccine at 6, 9, and 12 weeks of age \[[@ref38]\]. Evolutionary changes within the viral genome occurred since CPV-2 appeared in 1978 in the United States \[[@ref39]\], producing the emergence of new variants of CPV-2, which involves structural aa substitutions in the capsid of the virus, also resulting in antigenic changes for each variant \[[@ref40]\]. There were more than six AA changes in the capsid protein that differed from the new variants when compared with the original CPV-2 \[[@ref32]\], but one specific mutation located in residue 426 of the *VP2* gene \[[@ref9]\] resulted in a change of Asn-Asp-Glu between CPV-2a, CPV-2b, and CPV-2c, respectively, and this produced a biological change to be considered in natural infections within the dog population. A recent discovery of a new mutation in residue 514 (Ala-Ser) was reported in Argentina \[[@ref41]\] and Colombia \[[@ref16]\], and our findings showed a similar mutation in this residue. Therefore, we can consider the possibility of a new variant of CPV-2a emerging in South America that could possibly be related to a poor protection in vaccinated dogs (samples 1, 10, and 19), without discarding that the lack of information of vaccination schedule in these animals make difficult to support entirely this hypothesis. We can also mention that the biological impact of this single substitution (Ala514Ser) is not determined, making necessary to perform more studies to define the real impact of this change in the *VP2* protein. A substitution in residue 139 of Val, replacing Ile in sample 8 (CPV-2c), was also shown in isolates from Hungary belonging to CPV-2 strains \[[@ref42]\]. An unusual mutation in residue 297 from Ser to Asn was present in sample 1 (CPV-2a), which was not being reported consistently in parvovirus research, with just one strain isolated in Argentina \[[@ref43]\]. The mutation present in sample 24 (CPV-2b) in residue 322 from Thr to Ser was also a change reported only in China (2012) and South Korea (2007) (accession codes: KJ438802 and FJ197823). The mutation in residue 324 of sample 1 (CPV-2a) is a widely distributed change that was reported in Uruguay, China, Taiwan, and Nigeria \[[@ref31],[@ref44]-[@ref46]\]. Our results showed a prevalence of 20/35 (57.1%) for CPV-2a, 3/35 (8.5%) for CPV-2b, and 12/35 (34.3%) for CPV-2c. These variants were genetically characterized and demonstrated the complete spread of every known CPV-2 variant in Quito City, and our results corroborated the results of Aldaz *et al*. \[[@ref15]\], who described an important prevalence of CPV-2a and CPV-2c in the central region of Ecuador. We also confirmed the spread of CPV-2c in South America \[[@ref12]-[@ref15]\]. Ribbon diagrams detailed in [Figure-3](#F3){ref-type="fig"} show substitutions along the structure of *VP2* protein. The EC/C3 (CPV-2) was used to construct the 3D view of the *VP2* protein and the location of all substitutions of the four complete sequences is located in each segment. Among the aa substitutions of sample 1 in residues within Loop 1-4 already reported by other researchers \[[@ref7],[@ref33]\], the additional substitution in residue 514 appears out of the most antigenic region of the protein \[[@ref47]\], not making clear the possible effect that this may have on the antigenic function of the viral capsid. Substitution in residue 514 is shown in [Figure-4](#F4){ref-type="fig"}, showing no more structural changes than a loss of a molecule of oxygen.

Conclusion {#sec1-5}
==========

Considering these results, we can conclude that the presence of these variants in Ecuador corresponds with those described and distributed around the world, and the isolates that show the new mutations should be studied as possible new variants or subvariants emerging in this region of South America.
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